2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure

Chern En Chiang, Chung Lieh Hung, Yen Wen Wu, Tsung Hsien Lin, Kwo Chang Ueng, Shih Hsien Sung, Cho Ka I. Wu, Ting Hsing Chao, Hung Ju Lin, Yen Hung Lin, Jin Long Huang, Michael Yu Chih Chen, Po Lin Lin, Tze Fan Chao, Hao Min Cheng, Ming En Liu, Tzung Dau Wang, Hung I. Yeh, Yi Heng LI., Ping Yen LiuWei Hsian Yin, I. Chang Hsieh, Chun Chieh Wang, Chen Huan Chen, Pao Hsien Chu, Shing Jong Lin, San Jou Yeh, Jiunn Lee Lin, Juey Jen Hwang, Huei Fong Hung, Wen Jone Chen, Charles Jia Yin Hou

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure. Based on most updated information, this consensus provides rationales for prioritization, rapid sequencing, and in-hospital initiation of both foundational and additional therapies for patients with chronic heart failure.

Original languageEnglish
Pages (from-to)361-390
Number of pages30
JournalActa Cardiologica Sinica
Issue number3
Publication statusPublished - May 2023


  • Asia
  • Chronic heart failure
  • Consensus
  • Foundational therapy
  • Left ventricular ejection fraction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of '2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure'. Together they form a unique fingerprint.

Cite this